Daewoong Pharmaceutical's Nabota Launches in Qatar for the First Time in Korea... Expands into Key Middle Eastern Markets

Third Entry Following Saudi Arabia and the UAE

On the 30th of last month, the Nabota Launch Symposium was held in Doha, Qatar. Photo by Daewoong Pharmaceutical

Daewoong Pharmaceutical's high-purity, high-quality botulinum toxin, Nabota, has entered Qatar?one of the key global markets?for the first time among domestic products, further strengthening its strategy to target the high-growth potential Middle Eastern market.

Daewoong Pharmaceutical announced on June 5 that it officially launched Nabota at a launch symposium held recently in Doha, Qatar. With this launch, Nabota has now entered all three Gulf coastal countries?Qatar, Saudi Arabia, and the UAE?which are considered major targets for K-beauty.

The Gulf coastal countries refer to the six member states of the Gulf Cooperation Council (GCC). All of these countries are oil producers, have high national income levels, and show strong interest in beauty and cosmetic procedures, making them markets with significant growth potential. Active exchanges based on linguistic and cultural similarities are also expected to create synergy effects between the countries.

In particular, as of 2024, Qatar is a high-income nation with a per capita GDP of approximately $80,000 (about 109 million KRW), and demand for premium botulinum toxin is rapidly increasing in this market. Along with the UAE and Saudi Arabia, Qatar wields significant influence in the Middle East and North Africa region, making Nabota's entry into the market highly strategic.

To commemorate the launch, Daewoong Pharmaceutical and its partner company held a launch symposium on the 30th of last month at The St. Regis Hotel in Doha. The event was attended by about 200 local medical professionals, as well as key opinion leaders (KOLs) in the field of aesthetics and plastic surgery, including Ahmed Ibrahim from Qatar, Abdulkader Lammou from the UAE, and Koo Boncheol, Director of Naeum Dermatology in Korea. They introduced the excellence of Nabota and its differentiated treatment techniques.

Speaking as a lecturer at the event, Director Koo Boncheol said, "Nabota is characterized by its rapid and precise effects, making it the optimal product for precise procedures such as Nabolift, where the toxin is micro-injected into the skin layer to not only treat wrinkles but also adjust facial contours and expressions." He added, "This launch event was meaningful as it confirmed the high level of interest among Middle Eastern medical professionals in Korea's advanced procedural know-how."

'Nabolift' is a proprietary procedure developed by Daewoong Pharmaceutical, in which botulinum toxin is micro-injected into the skin layer to induce lifting, wrinkle improvement, and collagen production.

Dr. Abdulkader Lammou added, "Given the limited number of botulinum toxin products registered in Qatar, this event demonstrated the high level of interest among medical professionals in Nabota." He continued, "It was very meaningful to be able to discuss the clinical safety and efficacy of Nabota," sharing the response from Middle Eastern medical professionals.

Going forward, Daewoong Pharmaceutical plans to further expand brand awareness by conducting campaigns across Qatar and the UAE that combine differentiated procedures such as Nabolift, and will continue to strengthen collaboration with local partners.

Yoon Junsu, Head of the Nabota Business Division, commented on future strategy, saying, "This launch is significant in that it adds Qatar?one of the core Middle Eastern markets?as a strategic base country. We will actively expand our business throughout the Middle East, leveraging Nabota's quality competitiveness and proprietary procedures such as Nabolift."

This content was produced with the assistance of AI translation services.